Cover Image
Market Research Report

Diarrhea and Constipation Drug Development Pipeline Review, 2018

Published by GlobalData Product code 676512
Published Content info 93 Pages
Delivery time: 1-2 business days
Price
Back to Top
Diarrhea and Constipation Drug Development Pipeline Review, 2018
Published: July 30, 2018 Content info: 93 Pages
Description

Summary:

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. There are 54 products in development for this indication and molecular targets present in the pipeline landscape include cystic fibrosis transmembrane conductance regulator and glucagon like peptide 2 receptor.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. There are 25 products in development for this indication and molecular targets present in the pipeline landscape include 5-hydroxytryptamine receptor 4 and heat stable enterotoxin receptor.

Companies operating in this pipeline space include Synthetic Biologics, Allergan and Ardelyx.

This report "Diarrhea and Constipation Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for diarrhea and constipation, and features dormant and discontinued products.

Scope:

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy:

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Contents
Product Code: GBIHC041IDB

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Diarrhea and Constipation Report Coverage
  • 2.2. Constipation - Overview
  • 2.3. Diarrhea - Overview

3. Therapeutics Development

  • 3.1. Constipation
  • 3.2. Diarrhea

4. Therapeutics Assessment

  • 4.1. Constipation
  • 4.2. Diarrhea

5. Companies Involved in Therapeutics Development

  • 5.1. Constipation
  • 5.2. Diarrhea

6. Dormant Projects

  • 6.1. Constipation
  • 6.2. Diarrhea

7. Discontinued Products

  • 7.1. Constipation
  • 7.2. Diarrhea

8. Product Development Milestones

  • 8.1. Constipation
  • 8.2. Diarrhea

9. Appendix

  • 9.1. Methodology
  • 9.2. Coverage
  • 9.3. Secondary Research
  • 9.4. Primary Research
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Constipation
  • Table 2: Number of Products under Development by Companies, Constipation
  • Table 3: Number of Products under Development by Universities/Institutes, Constipation
  • Table 4: Products under Development by Companies, Constipation
  • Table 5: Products under Development by Universities/Institutes, Constipation
  • Table 6: Number of Products under Development for Diarrhea
  • Table 7: Number of Products under Development by Companies, Diarrhea
  • Table 8: Number of Products under Development by Universities/Institutes, Diarrhea
  • Table 9: Products under Development by Companies, Diarrhea
  • Table 10: Products under Development by Universities/Institutes, Diarrhea
  • Table 11: Number of Products by Stage and Target, Constipation
  • Table 12: Number of Products by Stage and Mechanism of Action, Constipation
  • Table 13: Number of Products by Stage and Route of Administration, Constipation
  • Table 14: Number of Products by Stage and Molecule Type, Constipation
  • Table 15: Number of Products by Stage and Target, Diarrhea
  • Table 16: Number of Products by Stage and Mechanism of Action, Diarrhea
  • Table 17: Number of Products by Stage and Route of Administration, Diarrhea
  • Table 18: Number of Products by Stage and Molecule Type, Diarrhea
  • Table 19: Constipation - Pipeline by Allergan Plc
  • Table 20: Constipation - Pipeline by Ardelyx Inc
  • Table 21: Constipation - Pipeline by Braintree Laboratories Inc
  • Table 22: Constipation - Pipeline by Dong-A ST Co Ltd
  • Table 23: Constipation - Pipeline by EA Pharma Co Ltd
  • Table 24: Constipation - Pipeline by Ironwood Pharmaceuticals Inc
  • Table 25: Constipation - Pipeline by Johnson & Johnson
  • Table 26: Constipation - Pipeline by MallInckrodt Plc
  • Table 27: Constipation - Pipeline by NGM Biopharmaceuticals Inc
  • Table 28: Constipation - Pipeline by RaQualia Pharma Inc
  • Table 29: Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd
  • Table 30: Constipation - Pipeline by SK Biopharmaceuticals Co Ltd
  • Table 31: Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd
  • Table 32: Constipation - Pipeline by Synthetic Biologics Inc
  • Table 33: Constipation - Pipeline by Vanda Pharmaceuticals Inc
  • Table 34: Constipation - Pipeline by Yuhan Corp
  • Table 35: Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd
  • Table 36: Diarrhea - Pipeline by Aegis Therapeutics LLC
  • Table 37: Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd
  • Table 38: Diarrhea - Pipeline by Albireo Pharma Inc
  • Table 39: Diarrhea - Pipeline by Allergan Plc
  • Table 40: Diarrhea - Pipeline by Ardelyx Inc
  • Table 41: Diarrhea - Pipeline by AzurRx BioPharma Inc
  • Table 42: Diarrhea - Pipeline by Bharat Biotech Ltd
  • Table 43: Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd
  • Table 44: Diarrhea - Pipeline by Cosmo Pharmaceuticals NV
  • Table 45: Diarrhea - Pipeline by DiscoveryBiomed Inc
  • Table 46: Diarrhea - Pipeline by Ferring International Center SA
  • Table 47: Diarrhea - Pipeline by GP Pharm SA
  • Table 48: Diarrhea - Pipeline by Kuhnil Pharmaceutical Co Ltd
  • Table 49: Diarrhea - Pipeline by Metacrine Inc
  • Table 50: Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd
  • Table 51: Diarrhea - Pipeline by Napo Pharmaceuticals Inc
  • Table 52: Diarrhea - Pipeline by Nippon Shinyaku Co Ltd
  • Table 53: Diarrhea - Pipeline by Novartis AG
  • Table 54: Diarrhea - Pipeline by Pfizer Inc
  • Table 55: Diarrhea - Pipeline by Prokarium Ltd
  • Table 56: Diarrhea - Pipeline by Protagonist Therapeutics Inc
  • Table 57: Diarrhea - Pipeline by RaQualia Pharma Inc
  • Table 58: Diarrhea - Pipeline by RedHill Biopharma Ltd
  • Table 59: Diarrhea - Pipeline by RxBio Inc
  • Table 60: Diarrhea - Pipeline by Scandinavian Biopharma Holding AB

List of Figures

  • Figure 1: Number of Products under Development for Constipation
  • Figure 2: Number of Products under Development by Companies, Constipation
  • Figure 3: Number of Products under Development for Diarrhea
  • Figure 4: Number of Products under Development by Companies, Diarrhea
  • Figure 5: Number of Products under Development by Universities/Institutes, Diarrhea
  • Figure 6: Number of Products by Targets, Constipation
  • Figure 7: Number of Products by Stage and Targets, Constipation
  • Figure 8: Number of Products by Top 10 Mechanism of Actions, Constipation
  • Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Constipation
  • Figure 10: Number of Products by Routes of Administration, Constipation
  • Figure 11: Number of Products by Stage and Routes of Administration, Constipation
  • Figure 12: Number of Products by Molecule Types, Constipation
  • Figure 13: Number of Products by Stage and Molecule Types, Constipation
  • Figure 14: Number of Products by Top 10 Targets, Diarrhea
  • Figure 15: Number of Products by Stage and Top 10 Targets, Diarrhea
  • Figure 16: Number of Products by Top 10 Mechanism of Actions, Diarrhea
  • Figure 17: Number of Products by Stage and Top 10 Mechanism of Actions, Diarrhea
  • Figure 18: Number of Products by Routes of Administration, Diarrhea
  • Figure 19: Number of Products by Stage and Routes of Administration, Diarrhea
  • Figure 20: Number of Products by Top 10 Molecule Types, Diarrhea
  • Figure 21: Number of Products by Stage and Top 10 Molecule Types, Diarrhea
Back to Top